Document:

EX-10.4

 Exhibit 10.4 

ONCORUS, INC. 

2016 EQUITY INCENTIVE PLAN 

RESTRICTED STOCK GRANT NOTICE 

Oncorus, Inc. (“Company”), pursuant to its 2016 Equity Incentive Plan (“Plan”), issues to Participant,
in exchange for Participant’s past or future services actually or to be rendered to the Company and such other applicable consideration specified below, the number of shares of Common Stock set forth below (“Shares”).
The Shares are subject to all of the terms and conditions as set forth in this Restricted Stock Grant Notice (“Grant Notice”) and in the Restricted Stock Agreement, the Plan, the Assignment Separate from Certificate and the
Joint Escrow Instructions, all of which are attached to this Grant Notice and incorporated into this Grant Notice in their entirety. Capitalized terms not explicitly defined in this Grant Notice but defined in the Plan or the Restricted Stock
Agreement will have the same definitions as in the Plan or the Restricted Stock Agreement. If there is any conflict between the terms in this Grant Notice and the Plan, the terms of the Plan will control. 

 

			
	Participant:	  	[____________]
		
	Date of Issuance:	  	[____________]
		
	Vesting Commencement Date:	  	[____________]
		
	Number of Shares Subject to Award:	  	[____________]
		
	Purchase Price:	  	[____________]

  

			
	Vesting Schedule:	  	The Shares will vest and become Vested Shares in accordance with the following vesting schedule:
		
		  	[Insert applicable vesting schedule, as well as any special vesting provisions (i.e., accelerated vesting upon termination and/or change in control-related vesting)]
		
		  	In the event Participant’s Continuous Service terminates for any reason, all Unvested Shares as of the date of such termination of Continuous Service shall immediately and automatically be forfeited by the Participant and
returned to the Company in accordance with and pursuant to the provisions of Section 4 of the Restricted Stock Agreement.

 [Remainder of page intentionally left blank] 

 Additional Terms/Acknowledgements: The undersigned Participant acknowledges receipt of, and
understands and agrees to, this Grant Notice, the Restricted Stock Agreement and the Plan. The Participant further acknowledges that as of the Date of Issuance, this Grant Notice, the Restricted Stock Agreement (and the other attachments hereto) and
the Plan set forth the entire understanding between the Participant and the Company regarding the acquisition of stock in the Company and supersede all prior oral and written agreements on that subject. 

 

									
	ONCORUS, INC.:	 		  	PARTICIPANT:
				
	By:	 	  
	 		  	  

		 	Signature	 	            	  	[Participant Name]
					
	Title:	 	  
	 		  	Date:	  	                                      
                                         
                 
	Date:	 	  
	 		  		  	

 ATTACHMENTS: 

 

			
	Attachment I:	  	Restricted Stock Agreement
		
	Attachment II:	  	2016 Equity Incentive Plan
		
	Attachment III:	  	Assignment Separate From Certificate
		
	Attachment IV:	  	Joint Escrow Instructions
		
	Attachment V:	  	Sample 83(b) Election
		
	Attachment VI:	  	Consent to Receive Notices By Electronic Transmission

 SIGNATURE PAGE TO ONCORUS, INC. 

RESTRICTED STOCK GRANT NOTICE 

 ATTACHMENT I 

ONCORUS, INC. 

2016 EQUITY INCENTIVE PLAN 

RESTRICTED STOCK AGREEMENT 

Pursuant to the Restricted Stock Grant Notice (“Grant Notice”), this Restricted Stock Agreement
(“Agreement”), and its 2016 Equity Incentive Plan (“Plan”) Oncorus, Inc. (“Company”) has issued to you, in exchange for the Purchase Price set forth in the Grant Notice and/or
in consideration of your past or future services actually or to be rendered to the Company, the number of Shares of Common Stock indicated in the Grant Notice (“Shares”). Capitalized terms not explicitly defined in this
Agreement but defined in the Plan or the Grant Notice will have the same definitions as in the Plan or the Grant Notice. If there is any conflict between the terms in this Agreement and the Plan, the terms of the Plan will control, unless otherwise
specifically provided. 
 The details of your award, in addition to those set forth in the Grant Notice and the Plan, are as follows: 

1. VESTING. 

(a) Subject to the limitations contained in this Agreement, the Shares will vest pursuant to the Vesting Schedule in the Grant Notice, provided
that vesting will cease upon the termination of your Continuous Service. 
 (b) For purposes hereof, “Vested Shares”
will mean Shares that have vested in accordance with the Vesting Schedule set forth on the Grant Notice or this Section 1 and with respect to which the risk of forfeiture described in Section 4(a) below has lapsed (the “Vesting
Schedule”), and “Unvested Shares” will mean Shares that have not vested in accordance with the Vesting Schedule or this Section 1 and that remain subject to the risk of forfeiture described in
Section 4(a) below. 
 (c) If any payment or benefit you would receive pursuant to a Change in Control from the Company or otherwise
(“Payment”) would (i) constitute a “parachute payment” within the meaning of Section 280G of the Code (as defined in the Plan), and (ii) but for this sentence, be subject to the excise tax imposed by
Section 4999 of the Code (the “Excise Tax”), then such Payment shall be equal to the Reduced Amount. The “Reduced Amount” shall be either (x) the largest portion of the Payment that would
result in no portion of the Payment being subject to the Excise Tax or (y) the largest portion, up to and including the total, of the Payment, whichever amount, after taking into account all applicable federal, state and local employment taxes,
income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in your receipt, on an after-tax basis, of the greater amount of the Payment notwithstanding that all or some
portion of the Payment may be subject to the Excise Tax. If a reduction in payments or benefits constituting “parachute payments” is necessary so that the Payment equals the Reduced Amount, reduction shall occur in the following order
unless you elect in writing a different order (provided, however, that such election shall be subject to Company approval if made on or after the effective date of the event that triggers the Payment): reduction of cash payments; cancellation of
accelerated vesting of Stock Awards (as defined in the Plan); reduction of employee benefits. In the event that acceleration of vesting of Stock Award compensation is to be reduced, such acceleration of vesting shall be cancelled in the reverse
order of the date of grant of your Stock Awards (i.e., earliest granted Stock Award cancelled last) unless you elect in writing a different order for cancellation. The Company shall bear all expenses with respect to the determinations required to be
made hereunder. Any good faith determinations of the accounting firm or other person or entity engaged by the Company in order to make such determinations required under this section shall be final, binding and conclusive upon you and the Company.

  
 1. 

 2. NUMBER OF
SHARES. The number of Shares and class of securities subject to this Award may be adjusted from time to time for Capitalization Adjustments. In the event of any such Capitalization Adjustments, any
additional Shares of Common Stock that you receive will be subject to the same vesting requirements and vesting schedule that is applicable to the Shares with respect to which such additional Shares relate. 

3. SECURITIES LAW COMPLIANCE. The Shares are not
registered under the Securities Act. At this time, the Company has determined that the issuance of the Shares under this Agreement is exempt from the registration requirements of the Securities Act. If the Company determines at any time that an
exemption from the registration requirements of the Securities Act was not available or that the issuance of the Shares otherwise would not comply with any other applicable laws and regulations, then the Company will not be obligated to issue the
Shares or may rescind the award to you. 
 4. FORFEITURE OF UNVESTED SHARES.

 (a) Forfeiture of Unvested Shares. In the event that your Continuous Service terminates for any reason, then (i) any
Unvested Shares as of the date of such termination (after giving effect to any accelerated vesting provided for under the Vesting Schedule or Section 1 above), and (ii) any Vested Shares, if the Company has terminated your Continuous
Service for Cause (as defined in the plan), in either case, shall immediately and automatically be forfeited and returned to the Company for the Reacquisition Price (as defined below) without any required action or notice to you. This forfeiture
with respect to Vested Shares is specifically intended to supersede any repurchase limitations that may be contained the Plan (which otherwise may provide that vested shares can only be repurchased for no less than fair market value). You hereby
agree to take whatever action the Company determines necessary to effectuate the Company’s reacquisition of the Shares and the return of such Shares to the Company. Following such forfeiture and reacquisition, the Company will become the legal
and beneficial owner of the Shares that were forfeited and reacquired and all rights and interests in and related to such Shares, and the Company will have the right to transfer to its own name the Shares being reacquired by the Company without
further action by you. For purposes of this Agreement, the term “Reacquisition Price” shall mean the lower of the original per share Purchase Price stated in the Grant Notice (which, for clarity may be $0) (subject to
adjustment for Capitalization Adjustments pursuant to the Plan), or the Fair Market Value of such Shares as of the date of such termination of Continuous Service. 

(b) The Reacquisition Price and the Repurchase Price may be delivered to you (as determined by the Company) in cash, a promissory note, by
offsetting and canceling any indebtedness then owed to the Company or any combination of the foregoing. 
 (c) Corporate Transactions.
In the event of a Corporate Transaction, the Company may provide that the forfeiture and reacquisition provisions of Section 4(a) may be assigned by the Company to the surviving or acquiring corporation (or the surviving or acquiring
corporation’s parent company), if any, in connection with the Corporate Transaction or that such provisions and restrictions may lapse in connection with the Corporate Transaction. To the extent the forfeiture and reacquisition provisions of
Section 4(a) remain in effect following a Corporate Transaction, such provisions shall apply to the new capital stock, cash or other property received in exchange for the Shares in consummation of the Corporate Transaction. 

  
 2. 

 5. TRANSFER
RESTRICTIONS. You are not permitted and agree that you will not sell, assign, hypothecate, donate, encumber or otherwise dispose of all or any part of the Unvested Shares or any interest in the
Unvested Shares while such Shares are subject to the risk of forfeiture described in Section 4(a) above; provided, however, that an interest in the Unvested Shares may be transferred pursuant to a domestic relations order as defined in
the Code. In the case of Vested Shares, you will not sell, assign, hypothecate, donate, encumber or otherwise dispose of all or any part of the Vested Shares or any interest in the Vested Shares except in compliance with this Agreement (including,
without limitation, Section 6), the Company’s bylaws, any shareholders’ agreement that you may be required to execute, and applicable securities laws. For clarity, no sale, transfer or other disposition of the Vested Shares or any
interest in the Vested Shares may occur unless the Company has first determined that such sale, transfer or other disposition is permitted by applicable securities laws (even if otherwise allowed by this Agreement and the Company’s corporate
governance documents). 
 6. RIGHT OF FIRST
REFUSAL. The Company shall have a right of first refusal, as described below, with respect to any voluntary or involuntary sale, assignment, gift, donation, pledge, or other disposition (each a
“Transfer”) of Vested Shares by you, provided, however, that no such right of first refusal shall exist in the case of a sale, transfer of other disposition by you of Vested Shares to a
third-party in connection with a Change in Control transaction. In addition, the term Transfer does not include a transfer of Vested Shares for no consideration to your Immediate Family (as defined below), provided that such Immediate Family Member
agrees in writing to hold the Vested Shares so transferred subject to the provisions of this Agreement (including, without limitation, this Section 6), and that there will be no further transfer of such Vested Shares except in accordance with
the terms of this Section 6. As used herein, the term “Immediate Family” will mean your spouse (or domestic partner), the lineal descendant or antecedent, father, mother, brother or sister, child, adopted child,
grandchild or adopted grandchild of you or your spouse (or domestic partner), or the spouse (or domestic partner) of any child, adopted child, grandchild or adopted grandchild of you or your spouse (or domestic partner). If you desire or are
required to Transfer some or all of the Vested Shares during your lifetime, you must, before effecting any such Transfer (and to the extent otherwise not precluded by any court or tribunal) offer to sell the Vested Shares proposed for Transfer (the
“Offered Shares”) to the Company by means of a written notice (the “Offer Notice”) to the Company stating (A) the number of Offered Shares, (B) the name and address of the third party to whom
the Offered Shares will be Transferred, and (C) the purchase price and terms of payment for the Offered Shares determined in accordance with the following two sentences. If the proposed Transfer is in a sale in which you will receive something
of value for the Offered Shares, the purchase price and terms of payment will be as set forth in a bona-fide offer from a third party to purchase the Offered Shares, but in no event will the Company be required to pay you an amount for the Offered
Shares that is in excess of the Fair Market Value of the Offered Shares on the date the Company gives written notice to you electing to exercise its Purchase Right (as defined below) as determined in good faith by the Board. If the proposed Transfer
is other than in a sale in which you will not receive something of value for the Offered Shares (such as in an involuntary Transfer, or a gift, donation, or pledge), you shall state in the Offer Notice that no purchase price and terms of payment are
being proposed and that the purchase price and terms of payment will be Fair Market Value of the Offered Shares on the date the Company gives written notice to you electing to exercise its Purchase Right as determined in good faith by the Board. For
30 days after the Company’s receipt of the Offer Notice under this Section (the “Option Period”), the Company will have the right (but not the obligation) to purchase all or any portion of the Offered Shares (such right,
the “Purchase Right”). The Company may exercise the Purchase Right by giving written notice to you (or your legal representative) during the Option Period specifying the number of Offered Shares it is electing to purchase.
The Company may assign its Purchase Right hereunder in the discretion of the Board and such rights will be cumulative in the event more than one event occurs giving rise to a right. The purchase price with respect to any purchase pursuant to the
Purchase Right shall be paid to you in cash by no later than the end of the Option Period (or if the Offer Notice contains terms of payment that provide for payments to be made to you on dates occurring after the Option Period, then the Company may
make its payments on those same dates). In the event of a Change in Control, all payments hereunder shall be accelerated to the date of the Change in Control and 

  
 3. 

 
shall be due and payable at that time. Notwithstanding the above, the Company’s Purchase Right will expire at the first date upon which any security of the Company is listed (or approved for
listing) upon notice of issuance on a national securities exchange or quotation system. Any recipient or transferee of the Offered Shares from you under this Section 6 may not subsequently Transfer or otherwise dispose of the Offered
Shares unless permitted by the Company in its sole discretion. Any such recipient or transferee will become subject to the terms of this Agreement on the same basis as you. As a condition to your transfer of any Offered Shares, the recipient or
transferee must acknowledge their obligation to abide by the terms of this Agreement and must execute this Agreement or any other agreements required to be executed by shareholders of the Company as requested by the Company. 

7. ESCROW OF SHARES. As security for your
faithful performance of the terms of this Agreement and to ensure the availability for delivery of the Shares upon the forfeiture of any portion of the Shares pursuant to Section 4(a), you agree that the Shares issued to you will be held in
escrow pursuant to the terms of the Joint Escrow Instructions attached to the Grant Notice as ATTACHMENT IV. You agree to execute and deliver to the Secretary of the Company or the Secretary’s designee (the
“Escrow Agent”), two (2) Assignment Separate From Certificate forms (with date and number of shares blank) substantially in the form attached to the Grant Notice as ATTACHMENT III and deliver the
same, along with the certificate or certificates evidencing the shares, for use by the Escrow Agent pursuant to the terms of the Joint Escrow Instructions. 

8. RIGHTS AS STOCKHOLDER. Subject to the terms of this
Agreement, you will exercise all rights and privileges of a stockholder of the Company with respect to the Shares of Common Stock deposited in escrow. You will be deemed to be the holder of the Shares for purposes of receiving any dividends that may
be paid with respect to such Shares (which will be subject to the same vesting and forfeiture restrictions as apply to the Shares to which they relate) and for purposes of exercising any voting rights relating to such Shares, even if some or all of
such Shares have not yet vested and remain subject to forfeiture. 
 9. RESTRICTIVE LEGENDS. All
certificates representing the Common Stock issued under this Agreement will be endorsed with legends in substantially the following forms (in addition to any other legend that may be required by other agreements between you and the Company): 

(a) “THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO A RISK OF FORFEITURE, REPURCHASE RIGHT AND OTHER RESTRICTIONS AND
CONDITIONS SET FORTH IN A RESTRICTED STOCK AGREEMENT BETWEEN THE COMPANY AND THE REGISTERED HOLDER, OR SUCH HOLDER’S PREDECESSOR IN INTEREST, A COPY OF WHICH IS ON FILE AT THE COMPANY’S PRINCIPAL CORPORATE OFFICES. ANY TRANSFER OR
ATTEMPTED TRANSFER OF ANY SHARES SUBJECT TO SUCH RIGHT IS VOID WITHOUT THE PRIOR EXPRESS WRITTEN CONSENT OF THE COMPANY.” 
 (b)
“THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THE
SECURITIES UNDER SAID ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.” 
 (c) “THE
SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO CERTAIN RIGHTS OF REFUSAL GRANTED TO THE COMPANY AND ACCORDINGLY MAY NOT BE SOLD, ASSIGNED, TRANSFERRED, ENCUMBERED OR IN ANY MANNER DISPOSED OF EXCEPT IN CONFORMITY WITH THE TERMS OF THE BYLAWS
OF THE COMPANY AND/OR A RESTRICTED STOCK AGREEMENT BETWEEN THE COMPANY AND THE REGISTERED HOLDER, OR SUCH HOLDER’S PREDECESSOR IN INTEREST, A COPY OF WHICH IS ON FILE AT THE COMPANY’S PRINCIPAL CORPORATE OFFICES.” 

  
 4. 

 (d) Any legend required by appropriate blue sky officials. 

10. AWARD NOT A SERVICE
CONTRACT. Your receipt of the Shares is not an employment or service contract, and nothing in this Agreement will be deemed to create in any way whatsoever any obligation on your part to continue in
the employ of the Company or an Affiliate, or on the part of the Company or an Affiliate to continue your employment. In addition, nothing in your Award will obligate the Company or an Affiliate, their respective stockholders, boards of directors,
Officers or Employees to continue any relationship that you might have as a Director or Consultant for the Company or an Affiliate. 
 11.
WITHHOLDING OBLIGATIONS. 
 (a) At the time you are issued any Shares, or at any time thereafter as
requested by the Company, you hereby authorize withholding from payroll and any other amounts payable to you, and otherwise agree to make adequate provision for any sums required to satisfy the federal, state, local and foreign tax withholding
obligations of the Company or an Affiliate, if any, which arise in connection with the issuance or vesting of your Shares (including the filing of a Section 83(b) Election as provided in Section 14 of this Agreement) (the
“Withholding Taxes”). The Company may, in its sole discretion, satisfy all or any portion of the Withholding Taxes obligation relating to the issuance or vesting of the Shares (or the filing of a Section 83(b) Election)
by any of the following means or by a combination of such means: (i) withholding from any amounts otherwise payable to you by the Company; (ii) causing you to tender a cash payment; or (iii) withholding shares of Common Stock from the
shares of Common Stock issued or otherwise issuable to you with a Fair Market Value equal to the amount of such Withholding Taxes; provided, however, that the number of such shares of Common Stock withheld may not exceed the amount necessary
to satisfy the Company’s required tax withholding obligations using the minimum statutory withholding rates for federal, state, local and foreign tax purposes, including payroll taxes, that are applicable to supplemental taxable income. 

(b) Unless the tax withholding obligations of the Company and any Affiliate are satisfied, the Company will have no obligation to issue a
certificate for such Shares or release such Shares from any escrow provided for in this Agreement. 
 12. INVESTMENT
REPRESENTATIONS. In connection with your acquisition of the Common Stock under this Agreement, you represent to the Company the following: 

(a) You are aware of the Company’s business affairs and financial condition and have acquired sufficient information about the Company to
reach an informed and knowledgeable decision to acquire the Common Stock. You are acquiring the Common Stock for investment for your own account only and not with a view to, or for resale in connection with, any “distribution” thereof
within the meaning of the Securities Act. 
 (b) You understand that the Common Stock has not been registered under the Securities Act by
reason of a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of your investment intent as expressed in this Agreement. 
  

  
 5. 

 (c) You further acknowledge and understand that the Common Stock must be held indefinitely
unless the Common Stock is subsequently registered under the Securities Act or an exemption from such registration is available. You further acknowledge and understand that the Company is under no obligation to register the Common Stock. You
understand that the certificate evidencing the Common Stock will be imprinted with a legend that prohibits the transfer of the Common Stock unless the Common Stock is registered or such registration is not required in the opinion of counsel for the
Company. 
 (d) You are familiar with the provisions of Rules 144 and 701 under the Securities Act, as in effect from time to time,
which, in substance, permit limited public resale of “restricted securities” acquired, directly or indirectly, from the issuer thereof (or from an affiliate of such issuer), in a non-public offering
subject to the satisfaction of certain conditions. Rule 701 provides that if the issuer qualifies under Rule 701 at the time of issuance of the securities, such issuance will be exempt from registration under the Securities Act. In the event the
Company becomes subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act, the securities exempt under Rule 701 may be sold by you ninety (90) days thereafter, subject to the satisfaction of certain of the
conditions specified by Rule 144 and the market stand-off agreement described in Section 13. 

(e) In the event that the sale of the Common Stock does not qualify under Rule 701 at the time of issuance, then the Common Stock may be
resold by you in certain limited circumstances subject to the provisions of Rule 144, which requires, among other things: (i) the availability of certain public information about the Company; and (ii) the resale occurring following the
required holding period under Rule 144 after you have purchased, and made full payment of (within the meaning of Rule 144), the securities to be sold. 

(f) You further understand that at the time you wish to sell the Common Stock there may be no public market upon which to make such a sale, and
that, even if such a public market then exists, the Company may not be satisfying the current public current information requirements of Rule 144 or 701, and that, in such event, you would be precluded from selling the Common Stock under Rule 144 or
701 even if the minimum holding period requirement had been satisfied. 
 13. MARKET STAND-OFF AGREEMENT. By acquiring shares of Common Stock under this Agreement, you agree that you will not sell, dispose of, transfer, make any short sale
of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale with respect to any shares of Common Stock or other securities of the Company held by you, for a period of one hundred
eighty (180) days following the effective date of a registration statement of the Company filed under the Securities Act or such longer period as the underwriters or the Company will request to facilitate compliance with FINRA Rule 2711 or NYSE
Member Rule 472 or any successor or similar rules or regulation (the “Lock-Up Period”); provided, however, that nothing contained in this Section 13 will prevent the
exercise of a repurchase option, if any, in favor of the Company during the Lock-Up Period. You further agree to execute and deliver such other agreements as may be reasonably requested by the Company or the
underwriters that are consistent with the foregoing or that are necessary to give further effect thereto. In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to your shares of Common Stock until
the end of such period. You also agree that any transferee of any shares of Common Stock (or other securities) of the Company held by you will be bound by this Section 13. The underwriters of the Company’s stock are intended third party
beneficiaries of this Section 13 and will have the right, power and authority to enforce the provisions hereof as though they were a party hereto. 

14. TAX CONSEQUENCES. You agree to review with your own tax advisors the federal, state, local and
foreign tax consequences of this investment and the transactions contemplated by this Agreement. You will rely solely on your advisors and not on any statements or representations of the Company or any of its agents. You understand that you (and not
the Company) will be responsible for your own tax liability that may arise as a result of this investment or the transactions contemplated by this 

  
 6. 

 
Agreement. You understand that Section 83 of the Code taxes as ordinary income to you the fair market value of the Shares of Common Stock issued to you under this Agreement as of the date
any restrictions on the Shares lapse (that is, as of the date on which part or all of the Shares vest). In this context, “restriction” includes the risk of forfeiture with respect to some or all of the Shares set forth above. You
understand that you may elect to be taxed at the time the Common Stock is issued to you pursuant to this Agreement, rather than when and as the risk of forfeiture with respect to the Shares expires, by filing an election under Section 83(b) of
the Code (an “83(b) Election”) with the Internal Revenue Service within 30 days after the date you acquire Shares of Common Stock pursuant to this Agreement. A sample 83(b) Election is attached as Attachment V for
convenience. Even if the fair market value of the Common Stock at the time it is issued equals the amount paid for the Common Stock, the 83(b) Election must be made to avoid income under Section 83(a) in the future. You understand that failure
to file an 83(b) Election in a timely manner may result in adverse tax consequences for you. You further understand that you must file an additional copy of the 83(b) Election with your federal income tax return for the calendar year in which you
make the 83(b) Election. You acknowledge that the foregoing is only a summary of the effect of U.S. federal income taxation with respect to issuance of the Common Stock pursuant to this Agreement, and does not purport to be complete. You further
acknowledge that notwithstanding the inclusion of a sample 83(b) Election as Attachment V, the Company has directed you to seek independent advice regarding the applicable provisions of the Code, the income tax laws of any municipality, state or
foreign country in which you may reside, and the tax consequences of your death. You assume all responsibility for filing an 83(b) Election and paying all taxes resulting from the 83(b) Election or the lapse of the restrictions on the Common Stock.
YOU ACKNOWLEDGE THAT NOTWITHSTANDING THE INCLUSION OF A SAMPLE 83(B) ELECTION AS ATTACHMENT V, IT IS YOUR OWN RESPONSIBILITY, AND NOT THE COMPANY’S, TO FILE A TIMELY 83(B) ELECTION. THE COMPANY AND ITS LEGAL COUNSEL CANNOT ASSUME RESPONSIBILITY
FOR FAILURE TO FILE THE 83(B) ELECTION IN A TIMELY MANNER UNDER ANY CIRCUMSTANCES. 
 15.
NOTICES. Any notices provided for in this Agreement or the Plan will be given in writing and will be deemed effectively given upon receipt or, in the case of notices delivered by the Company to
you, five days after deposit in the U.S. mail, postage prepaid, addressed to you at the last address you provided to the Company. 
 16.
MISCELLANEOUS. 
 (a) As a condition to the Company’s issuance of any Shares of Common Stock under this Agreement,
the Company may require you to execute certain customary agreements entered into with the holders of capital stock of the Company, including without limitation a right of first refusal and co-sale agreement,
stockholders agreement and a voting agreement. 
 (b) The rights and obligations of the Company under this Agreement will be transferable by
the Company to any one or more persons or entities, and all covenants and agreements hereunder will inure to the benefit of, and be enforceable by the Company’s successors and assigns. Your rights and obligations under this Agreement may only
be assigned with the prior written consent of the Company. 
 (c) You agree upon request to execute any further documents or instruments
necessary or desirable in the sole determination of the Company to carry out the purposes or intent of this Agreement. 
 (d) You acknowledge
and agree that you have reviewed this Agreement in its entirety, have had an opportunity to obtain the advice of counsel prior to executing and accepting the Shares and fully understand all provisions of this Agreement. 

  
 7. 

 17. GOVERNING PLAN
DOCUMENT. This Agreement and the Shares issued to you hereunder are subject to all the terms of the Plan, the terms of which are hereby made a part of this Agreement, and is further subject to all
interpretations, amendments, rules and regulations which may from time to time be promulgated and adopted pursuant to the Plan. In the event of any conflict between the provisions of this Agreement and those of the Plan, the provisions of the Plan
will control. 
 18. CAPITALIZATION ADJUSTMENTS. In the event of a
Capitalization Adjustment, then any and all new, substituted or additional securities or other property to which you are entitled by reason of your ownership of the Shares will be immediately subject to the rights, restrictions and obligations set
forth in this Agreement with the same force and effect as the Shares subject to the those rights, restrictions and limitations immediately before such event. 

*         *         * 

This Restricted Stock Agreement will be deemed to be signed by the Company and Participant upon the signing by Participant of the Restricted
Stock Grant Notice to which it is attached. 

  
 8. 

 ATTACHMENT II 

ONCORUS, INC. 

2016 EQUITY INCENTIVE PLAN 

(Attached) 

 ATTACHMENT III 

ASSIGNMENT SEPARATE FROM CERTIFICATE 

FOR VALUE RECEIVED and pursuant to that Restricted Stock Grant Notice and
Restricted Stock Agreement, each dated [Date of Grant] (together, the “Agreement”), [Participant] hereby sells, assigns and transfers unto ONCORUS, INC., a Delaware corporation (the
“Company”) ________________________ Shares of the Common Stock of the Company (the “Common Stock”), standing in the undersigned’s name on the books of the Company represented
by Certificate No(s). _____ and does hereby irrevocably constitute and appoint the Company’s Secretary as attorney-in-fact to transfer the said Common Stock on
the books of the Company with full power of substitution in the premises. This Assignment Separate From Certificate may be used only in accordance with and subject to the terms and conditions of the Agreement, in connection with the
forfeiture, reacquisition or repurchase of Shares of Common Stock issued to the undersigned pursuant to the Agreement, and only to the extent that such Shares remain subject to forfeiture, reacquisition and/or repurchase under the Agreement. 

Dated:
                                         
        
  

			
	Signature:	 	  

		 	      [Participant]

 [INSTRUCTIONS: Please do not fill in any blanks other than the “Signature” line. The
purpose of this Assignment Separate From Certificate is to enable the Company to reacquire or repurchase Shares without requiring additional signatures on your part] 

 ATTACHMENT IV 

ONCORUS, INC. 
 JOINT
ESCROW INSTRUCTIONS 
 [Date of Grant] 
 Secretary 

Oncorus, Inc. 
 50 Hampshire Street, Suite 401 

Cambridge, MA 02139 
 Ladies and Gentlemen: 

As Escrow Agent for both Oncorus, Inc., Delaware corporation (the “Company”), and the undersigned recipient
(“Recipient”) of Common Stock of the Company (the “Common Stock”), you are hereby authorized and directed to hold the documents delivered to you pursuant to the terms of the Restricted Stock Grant
Notice (the “Grant Notice”), dated [Date of Grant], to which a copy of these Joint Escrow Instructions is attached as Attachment IV, and pursuant to the terms of the Restricted Stock Agreement (the
“Agreement”), which is Attachment I to the Grant Notice, in accordance with the following instructions: 
 1.
In the event Recipient ceases to render services to the Company or an affiliate of the Company during the vesting period set forth in the Grant Notice, the Company or its affiliate or assignee will give to Recipient and you a written notice
specifying the number of Shares of Common Stock that have not vested in accordance with the vesting schedule set forth in the Grant Notice (the “Unvested Shares”) to be transferred to the Company. Recipient and the Company
hereby irrevocably authorize and direct you to close the transaction contemplated by such notice in accordance with the terms of said notice. 

2. At the closing you are directed (a) to date any stock assignments necessary for the transfer in question, (b) to fill in
the number of Unvested Shares being transferred, and (c) to deliver the same, together with the certificate evidencing the Shares of Common Stock to be transferred, to the Company. 

3. Recipient irrevocably authorizes the Company to deposit with you any certificates evidencing Shares of Common Stock to be held by you
under these Joint Escrow Instructions and any additions and substitutions to said Shares as specified in the Grant Notice and the Agreement. Recipient does hereby irrevocably constitute and appoint you as Recipient’s attorney-in-fact and agent for the term of the escrow to execute with respect to such securities and other property all documents of assignment and/or transfer and all stock
certificates necessary or appropriate to make all securities negotiable and complete any transaction herein contemplated, including but not limited to any appropriate filing with state or government officials or bank officials. Subject to the
provisions of this paragraph 3, Recipient shall exercise all rights and privileges of a shareholder of the Company while the stock is held by you. 

4. This escrow shall terminate upon the exercise in full or expiration of the Company’s rights to reacquire or repurchase the
Shares, whichever occurs first. 

  
 1. 

 5. If at the time of termination of this escrow under Section 4 herein you
should have in your possession any documents, securities, or other property belonging to Recipient, you shall deliver all of the same to Recipient and will be discharged of all further obligations hereunder; provided, however, that if at the
time of termination of the escrow you are advised by the Company that the property subject to this escrow is the subject of a pledge or other security agreement, you shall deliver all such property to the pledgeholder or other person designated by
the Company. 
 6. Except as otherwise provided in these Joint Escrow Instructions, your duties hereunder may be altered, amended,
modified or revoked only by a writing signed by all of the parties hereto. 
 7. You will be obligated only for the performance of
such duties as are specifically set forth in these Joint Escrow Instructions and may rely and will be protected in relying or refraining from acting on any instrument reasonably believed by you to be genuine and to have been signed or presented by
the proper party or parties or their assignees. You will not be personally liable for any act you may do or omit to do hereunder as Escrow Agent or as attorney-in-fact
for Recipient while acting in good faith and any act done or omitted by you pursuant to the advice of your own attorneys will be conclusive evidence of such good faith. 

8. You are expressly authorized to disregard any and all warnings given by any of the parties to these Joint Escrow Instructions or by
any other person or corporation, excepting only orders or process of courts of law, and are hereby expressly authorized to comply with and obey orders, judgments or decrees of any court. In case you obey or comply with any such order, judgment or
decree of any court, you will not be liable to any of the parties hereto or to any other person, firm or corporation by reason of such compliance, notwithstanding any such order, judgment or decree being subsequently reversed, modified, annulled,
set aside, vacated or found to have been entered without jurisdiction. 
 9. You will not be liable in any respect on account of the
identity, authority or rights of the parties executing or delivering or purporting to execute or deliver the Grant Notice, the Agreement or any documents or papers deposited or called for hereunder. 

10. You will not be liable for the outlawing of any rights under any statute of limitations with respect to these Joint Escrow
Instructions or any documents deposited with you. 
 11. Your responsibilities as Escrow Agent under these Joint Escrow Instructions
will terminate if you will cease to be Secretary of the Company or if you will resign by written notice to the Company. In the event of any such termination, the Secretary of the Company will automatically become the successor Escrow Agent unless
the Company will appoint another successor Escrow Agent and Recipient hereby confirms the appointment of such successor as Recipient’s attorney-in-fact and agent to
the full extent of your appointment. 
 12. If you reasonably require other or further instruments in connection with these Joint
Escrow Instructions or obligations in respect to these Joint Escrow Instructions, the necessary parties to these Joint Escrow Instructions will join in furnishing such instruments. 

13. It is understood and agreed that should any dispute arise with respect to the delivery or ownership or right of possession of the
securities, you are authorized and directed to retain in your possession without liability to anyone all or any part of said securities until such dispute will have been settled either by mutual written agreement of the parties concerned or by a
final order, decree or judgment of a court of competent jurisdiction after the time for appeal has expired and no appeal has been perfected, but you will be under no duty whatsoever to institute or defend any such proceedings. 

  
 2. 

 14. Any notice required or permitted under these Joint Escrow Instructions will be
given in writing and will be deemed effectively given upon personal delivery, including delivery by express courier or five days after deposit in any U.S. Post Office, by registered or certified mail with postage and fees prepaid, addressed to each
of the other parties hereunto entitled at the following addresses, or at such other addresses as a party may designate by ten days’ written notice to each of the other parties hereto: 

 

			
	Company:	  	Oncorus, Inc.
		  	 50 Hampshire Street, Suite 401
 Cambridge, MA
02139

		  	Attention: President
		
	Recipient:	  	[Participant]
		  	[Address 1]
		  	 [Address 2]
 [Participant Email]

		
	Escrow Agent:	  	Oncorus, Inc.
		  	 50 Hampshire Street, Suite 401
 Cambridge, MA
02139

		  	Attention: Secretary

 15. You will be entitled to employ such legal counsel, including without limitation Cooley LLP,
and other experts as you may deem necessary to advise you in connection with your obligations hereunder, and you may rely upon the advice of such counsel, and may pay such counsel reasonable compensation therefor. The Company will be responsible for
all fees generated by such legal counsel in connection with your obligations hereunder. 
 16. This instrument will be binding upon
and inure to the benefit of the parties to these Joint Escrow Instructions, and their respective successors and permitted assigns. It is understood and agreed that references to “you” or “your” herein refer to the original Escrow
Agent and to any and all successor Escrow Agents. It is understood and agreed that the Company may at any time or from time to time assign its rights under the Grant Notice, the Agreement and these Joint Escrow Instructions in whole or in part. 

17. These Joint Escrow Instructions will be governed by and interpreted and determined in accordance with the laws of the State of
Delaware, as such laws are applied by Delaware courts to contracts made and to be performed entirely in Delaware by residents of that state. 

18. By signing these Joint Escrow Instructions you become a party hereto only for the purpose of said Joint Escrow Instructions; you do
not become a party to the Grant Notice or the Agreement. 
 [Remainder of page intentionally left blank] 

  
 3. 

 The undersigned have executed this JOINT ESCROW
INSTRUCTIONS as of the date set forth above. 
  

			
	RECIPIENT:
	
	[PARTICIPANT]
	
	  

	(Signature)

  

					
	COMPANY:
	
	ONCORUS, INC.
		
	By:	 	  

		 	Name:	 	Ted Ashburn
		 	Title:	 	Chief Executive Officer

  

	
	ESCROW AGENT:
	
	  

	JOHN MCCABE, SECRETARY

 SIGNATURE PAGE TO ONCORUS, INC. 

JOINT ESCROW INSTRUCTIONS 

 ATTACHMENT V 

SAMPLE 83(B) ELECTION 

[INTENTIONALLY OMITTED] 

 ATTACHMENT VI 

CONSENT TO RECEIVE NOTICES BY ELECTRONIC TRANSMISSION 

The undersigned stockholder (the “Stockholder”) of Oncorus, Inc., a Delaware corporation (the
“Company”), hereby consents to the delivery of stockholder notices by electronic transmission for all purposes and to the fullest extent permitted by law, including the fullest extent set forth in Section 232 of the
General Corporation Law of the State of Delaware (the “DGCL”). Notices by electronic transmission shall be delivered to the Stockholder as follows: 

1. If by electronic mail, such notices shall be sent to the electronic mail address set forth below the Stockholder’s
signature or to such other electronic mail address as shall be designated by the Stockholder in a written notice sent to: 
 Oncorus, Inc.

 [Address] 
 [Address] 

Attn: Secretary 
 2. If by
posting on an electronic network, such notices shall be posted for at least five (5) business days on the Company’s web site and the Stockholder shall be notified of such posting at least three (3) business days’ in
advance either (i) by electronic mail complying as to delivery with the terms of paragraph 1 above or (ii) by written notice to the Stockholder at the address set forth in the Company’s records. 

This consent applies to any and all notices required to be given to the Stockholder for any purpose, including under the DGCL and/or the
Company’s certificate of incorporation, bylaws or otherwise. This consent also applies to any and all notices required to be given to the Stockholder pursuant to any investors rights’, stockholders’, voting, right of first refusal and
co-sale, registration rights or other similar stockholder agreement in respect of the Company or its shares of capital stock, unless otherwise expressly indicated in the applicable agreement. All notices sent
by electronic mail will be considered given and received as of and on the date of electronic transmission thereof. 
 The undersigned
Stockholder hereby executes this consent as an instrument under seal as of the date set forth below. 
  

					
		 		  	STOCKHOLDER:
			
	Date of Execution:
                                         
                   	 	            	  	[PARTICIPANT]
			
		 		  	  

		 		  	(Signature)
			
		 		  	 [Email]

		 		  	Designated Stockholder email addressEX-10.10

 Exhibit 10.10 

 
 

 
 August 23, 2017 

Christophe Queva, PhD 
 Dear Christophe: 

On behalf of Oncorus, Inc., a Delaware corporation (the “Company”), I am pleased to offer you employment with the Company. The
purpose of this letter is to summarize the terms of your employment with the Company, should you accept our offer: 
 1. You will be employed
to serve on a full-time basis as Chief Scientific Officer effective on or around October 1, 2017. As the Chief Scientific Officer, you will report to the Chief Executive Officer (“CEO“). You will be responsible for duties as are
consistent with such position as well as other duties assigned by your manager and the Company. 
 2. Your base salary will be at the rate of
$13,333.34 per semi-monthly pay period, subject to tax and other withholdings as required by law. Such base salary may be adjusted from time to time in accordance with normal business practice and in the sole discretion of the Company. 

3. You may participate in any and all bonus and benefit programs that the Company establishes and makes available to its employees from time to
time, provided you are eligible under (and subject to all provisions of) the plan documents governing those programs. Subject to these programs, you will be eligible to receive a bonus targeted at 30% of your annualized base salary (on a pro-rated basis if you are employed for less than a full year) based on criteria to be mutually agreed upon between you and the CEO. The bonus and benefit programs made available by the Company, and the rules, terms
and conditions for participation in such benefit plans, may be changed by the Company at any time without notice. You will be eligible for sick leave and unlimited vacation in accordance with the Company’s sick leave and vacation policies. You
will be reimbursed for your business expenses in accordance with Company policy. You will be entitled to Directors and Officers insurance and such other insurance may be maintained by the Company. 

4. Subject to the approval of the Board of Directors, the Company will grant and/or award to you a combination of restricted stock
(“RSA”) and/or a stock option (“Options”) under the Company’s equity incentive plan (the “Stock Plan”) for the purchase of an aggregate of 1,000,000 shares of common stock at a price per share equal to the fair
market value at the time of Board approval. The Board will work with you on the mix of RSA and Options to build this position; in the case in which the RSA is issued to you below the 409A valuation obtained for the stock you will be required to pay
taxes for this gap. Also, in case of tax due, the Company may be required to withhold against the amount due at the time of your filing of the 83(b) election. The Option and/or RSA shall be subject to all terms, vesting schedules and other
provisions set forth in the Plan and in a separate option agreement or restricted share unit agreement, as applicable (collectively, the “Equity Agreement”). 

5. Provided you accept this offer on or before September 1, 2017, and provided you commence employment on or before October 1, 2017,
the Company will pay you a one-time relocation bonus in the amount of $50,000 less deductions required by law. This relocation bonus will be paid on the first regularly scheduled payroll date post-completion
of relocation. Should the Company terminate your employment for Cause or should you choose to leave the Company for any reason or fail to relocate to the Cambridge, MA area, in either case prior to the
one-year anniversary of your start date, you will be required to repay the Company a pro-rated share of the relocation bonus not earned based on time served. Should the
Company terminate your employment without Cause or if your employment terminates as a result of your death or disability, and provided you sign and allow to become effective the release of claims on the terms set forth in Section 11, no
repayment of the signing bonus shall be required. 

 6. You may be eligible to receive such future stock option grants as the Board of Directors
of the Company shall deem appropriate. 
 7. If your employment is terminated by the Company without Cause (as defined below) or you
terminate your employment for Good Reason (as defined below) and provided you execute and allow to become effective (within 60 days following the termination or such shorter period as may be directed by the Company) a release of claims in form
attached as Exhibit A (the “ Release Agreement”), (i) the Company will pay you as severance pay an aggregate amount equivalent to nine (9) months of your then current base salary (pro-rated, if
applicable), less all applicable taxes and withholdings, which severance pay will be paid ratably in accordance with the Company’ s regular payroll practices beginning in the Company’s first regular payroll cycle after the Release
Agreement becomes effective; provided, however, that if the 60th day referenced above occurs in the calendar year following the date of your termination, then the severance pay shall begin no earlier than January l of such subsequent calendar year;
and (ii) should you timely elect and be eligible to continue receiving group medical coverage pursuant to the “COBRA” law, and so long as the Company can provide such benefit without violating the nondiscrimination requirements of
applicable law, the Company will for a period of nine (9) months following your termination continue to pay the share of the premium for such coverage that is paid by the Company for active and similarly-situated employees who receive the same
type of coverage (The remaining balance of any premium costs shall timely be paid by you on a monthly basis for as long as, and to the extent that, you remain eligible for COBRA continuation). Additionally, if your employment by the Company is
terminated by the Company without Cause, or by you for Good Reason, the vesting schedule for your outstanding equity awards will be accelerated such that an additional twelve (12) months of vesting will be accelerated and become vested and
exercisable effective upon the termination; provided that if such termination occurs within two months prior to or within twelve (12) months following a Change of Control, the vesting schedule for your outstanding equity awards will be
accelerated in full such that 100% of such awards that are not then vested will be accelerated and become vested and exercisable effective upon the termination. Attached as Appendix A are the terms and conditions applicable to the payment of any
severance hereunder. 
 For purposes of this Agreement: 

“Cause” means any of: (a) your conviction of, or plea of guilty or nolo contendere to, any crime involving dishonesty or moral
turpitude or any felony; or (b) a good faith finding by the Company’s Board of Directors that you have (i) engaged in dishonesty, willful misconduct or gross negligence that has a material adverse effect on the Company,
(ii) committed an intentional act that materially injures the reputation, business or business relationships of the Company, (iii) materially breached the terms of any restrictive covenants or confidentiality agreement with the Company;
provided that in the case of (b) that you were given written notice of such violation or failure by the Board and a period of 30 days to cure (provided that the Board determines that such violation or failure is curable). 

“Change of Control” shall mean, regardless of form thereof, consummation of (a) the sale of all or substantially all of the
assets of the Company on a consolidated basis to an unrelated person or entity, (b) a merger, reorganization or consolidation in which the outstanding shares of capital stock of the Company are converted into or exchanged for securities of the
successor entity and the holders of the Company’s outstanding voting power immediately prior to such transaction do not own a majority of the outstanding voting power of the successor entity immediately upon completion of such transaction,
(c) the sale of all or a majority of the outstanding capital stock of the Company to an unrelated person or entity or (d) any other transaction in which the owners of the Company’s outstanding voting power immediately prior to such
transaction do not own at least a majority of the outstanding voting power of the successor entity immediately upon completion of the transaction; provided, however, that “Change of Control” shall not include any financing transaction of
the Company (whether public or private) that would otherwise be and/or trigger a “Change of Control” under (c) and/or (d) above. 

 “Good Reason” means the occurrence, without your prior written consent, of any of
the following events: (i) a material reduction in your authority, duties, or responsibilities; (ii) the relocation of the principal place at which you provide services to the Company by at least 50 miles and to a location such that your
daily commuting distance is increased; (iii) a material reduction of your base salary (other than in connection with, and in an amount substantially proportionate to, reductions made by the Company to the base salaries of other members of
management) and, provided further, that any reduction in base salary of more than ten percent (10%) shall constitute Good Reason; or (iv) the material breach by the Company of the Company’s equity incentive plan or the stock option
agreements governing certain stock options granted to you (as described in the offer letter) or any other material agreement between you and the Company, if any, concerning the terms and conditions of your employment, benefits or compensation or any
material breach by the Company of its obligations under this offer letter. No resignation will be treated as a resignation for Good Reason unless (x) you have given written notice to the Company of your intention to terminate your employment
for Good Reason, describing the grounds for such action, no later than 90 days after the first occurrence of such circumstances, (y) you have provided the Company with at least 30 days in which to cure the circumstances, and (z) if the
Company is not successful in curing the circumstance s, you end your employment within 60 days following the cure period in (y).You will be required to execute an Invention and Non-Disclosure Agreement, Non-Competition and Non-Solicitation Agreement in the form attached as Exhibit B, as a condition of employment. 

8. You represent that you are not bound by any employment contract, restrictive covenant or other restriction preventing (or that purports to
prevent) you from entering into employment with or carrying out your responsibilities for the Company, or which is in any way inconsistent with the terms of this letter. 

9. You agree to provide to the Company, within three days of your hire date, documentation of your eligibility to work in the United States, as
required by the Immigration Reform and Control Act of 1986. You may need to obtain a work visa in order to be eligible to work in the United States. If that is the case, your employment with the Company will be conditioned upon your obtaining a work
visa in a timely manner as determined by the Company. 
 10. This letter shall not be construed as an agreement, either expressed or implied,
to employ you for any stated term, and shall in no way alter the Company’s policy of employment at will, under which both you and the Company remain free to terminate the employment relationship, with or without cause, at any time, with or
without notice. Although your job duties, title, compensation and benefits, as well as the Company’s personnel policies and procedures, may change from time to time, the “at-will” nature of your
employment may only be changed by a written agreement signed by you and the Company’s Chief Executive Officer, which expressly states the intention to modify the at-will nature of your employment.
Similarly, nothing in this letter shall be construed as an agreement, either express or implied, to pay you any compensation or grant you any benefit beyond the end of your employment with the Company. 

11. In return for the compensation payments set forth in this letter, you agree to devote your full business time, best efforts, skill,
knowledge, attention, and energies to the advancement of the Company’s business and interests and to the performance of your duties and responsibilities as an employee of the Company and not to engage in any other business activities without
prior approval from the Company. 
 12. As an employee of the Company, you will be required to comply with all Company policies and
procedures. Violations of the Company’s policies may lead to immediate termination of your employment. Further, the Company’s premises, including all workspaces, furniture, documents, and other tangible materials, and all information
technology resources of the Company (including computers, data and other electronic files, and all internet and email) are subject to oversight and inspection by the Company at any time. Company employees should have no expectation of privacy with
regard to any Company premises, materials, resources, or information. 

 13. This offer letter is your formal offer of employment and supersedes any and all prior or
contemporaneous agreements, discussions and understandings, whether written or oral, relating to the subject matter of this letter or your employment with the Company. The resolution of any disputes under this letter will be governed by the laws of
the Commonwealth of Massachusetts. 
 If you agree with the provisions of this letter, please sign the enclosed duplicate of this letter in
the space provided below and return it to Stacy Gilroy, Director Operations by September 1, 2017. If you do not accept this offer by end of day September 1, 2017 the offer will be revoked. 

 

			
	Very Truly Yours,
	
	ONCORUS, INC.
		
	By:	 	 /s/ Mitchell Finer

		 	Name: Mitchell H. Finer, PhD
		 	Title: Chief Executive Officer

 The foregoing correctly sets forth the terms of my employment by Oncorus, Inc. 

 

							
	Date:	 	 August 29, 2017
	 	        	  	 /s/ Christophe Queva

Name: Christophe Queva

 APPENDIX A 

Payments Subject to Section 409A 
 1.
Subject to this Appendix A, any severance payments that may be due under the Agreement shall begin only upon the date of your “separation from service” (determined as set forth below) which occurs on or after the termination of your
employment. The following rules shall apply with respect to distribution of the severance payments, if any, to be provided to you under the Agreement, as applicable: 

(a) It is intended that each installment of the severance payments under the Agreement provided under shall be treated as a separate
“payment” for purposes of Section 409A. Neither the Company nor you shall have the right to accelerate or defer the delivery of any such payments except to the extent specifically permitted or required by Section 409A. 

(b) If, as of the date of your “separation from service” from the Company, you are not a “specified employee” (within the
meaning of Section 409A), then each installment of the severance payments shall be made on the dates and terms set forth in the Agreement. 

(c) If, as of the date of your “separation from service” from the Company, you are a “specified employee” (within the
meaning of Section 409A), then: 
 (i) Each installment of the severance payments due under the Agreement that, in accordance with the
dates and terms set forth herein, will in all circumstances, regardless of when your separation from service occurs, be paid within the short-term deferral period (as defined under Section 409A) shall be treated as a short-term deferral within
the meaning of Treasury Regulation Section 1.409A-1(b)(4) to the maximum extent permissible under Section 409A and shall be paid on the dates and terms set forth in the Agreement; and 

(ii) Each installment of the severance payments due under the Agreement that is not described in this Appendix A, Section 1(c)(i) and that
would, absent this subsection, be paid within the six-month period following your “separation from service” from the Company shall not be paid until the date that is six months and one day after such
separation from service (or, if earlier, your death), with any such installments that are required to be delayed being accumulated during the six-month period and paid in a lump sum on the date that is six
months and one day following your separation from service and any subsequent installments, if any, being paid in accordance with the dates and terms set forth herein; provided, however, that the preceding provisions of this sentence shall not apply
to any installment of payments if and to the maximum extent that that such installment is deemed to be paid under a separation pay plan that does not provide for a deferral of compensation by reason of the application of Treasury Regulation
1.409A-1(b)(9)(iii) (relating to separation pay upon an involuntary separation from service). Any installments that qualify for the exception under Treasury Regulation Section 1.409A-1(b)(9)(iii) must be
paid no later than the last day of your second taxable year following the taxable year in which the separation from service occurs. 
 2. The determination
of whether and when your separation from service from the Company has occurred shall be made and in a manner consistent with, and based on the presumptions set forth in, Treasury Regulation
Section 1.409A-1(h). Solely for purposes of this Appendix A, Section 2, “Company” shall include all persons with whom the Company would be considered a single employer under
Section 414(b) and 414(c) of the Code. 
 3. The Company makes no representation or warranty and shall have no liability to you or to any other person
if any of the provisions of the Agreement (including this Appendix) are determined to constitute deferred compensation subject to Section 409A but that do not satisfy an exemption from, or the conditions of, that section. 

 EXHIBIT A 

FORM OF SEPARATION AGREEMENT 

[Place on Company Letterhead] 
 VIA
HAND DELIVERY 
 [Insert Date] 
 [Insert
Name] 
 [Insert Address] 
 Dear [Insert
Name]: 
 In connection with the termination of your employment with [Insert Company Name] (the “Company”) on [Insert
Termination Date], you are eligible to receive the severance benefits described in paragraph 2 below if you sign and return this letter agreement to me by [Return Date] [and it becomes binding between you and the Company]. By signing and
returning this letter agreement [and not revoking your acceptance], you will be entering into a binding agreement with the Company and will be agreeing to the terms and conditions set forth in the numbered paragraphs below, including the
release of claims set forth in paragraph 3. Therefore, you are advised to consult with an attorney before signing this letter agreement and you have been given at least [seven (7) / twenty-one (21) /
forty-five (45)]1 days to do so. [If you sign this letter agreement, you may change your mind and revoke your agreement during the seven (7) day period after you have
signed it by notifying me in writing. If you do not so revoke, this letter agreement will become a binding agreement between you and the Company upon the expiration of the seven (7) day period.] 

If you choose not to sign and return this letter agreement by [Return Date] [or if you timely revoke your acceptance in
writing], you shall not receive any severance benefits from the Company. You will, however, receive payment for your final wages, any unpaid bonus, and any unused vacation time accrued through the Termination Date, as defined below, and
reimbursement for any unpaid business expenses. You may also, if eligible, elect to continue receiving group medical insurance pursuant to “COBRA.” Please consult the COBRA materials to be provided by the Company under separate cover for
details regarding these benefits. 
 The following numbered paragraphs set forth the terms and conditions that will apply if you timely sign
and return this letter agreement [and do not revoke it in writing within the seven (7) day period]. 
 1. Termination Date and
Resignation as a Director – Your effective date of termination from the Company is [Insert Termination Date] (the “Termination Date”). You agree to resign, as of the Termination Date, from your position as a Director of the
Company, and to sign and return to the Company all letters and documents that the Company may reasonably require in order to secure your resignation. As of the Termination Date, all salary payments from the Company will cease and any benefits you
had as of the Termination Date under Company-provided benefit plans, programs, or practices will terminate, except as required by federal or state law. 

2. Description of Severance Benefits – If you timely sign and return this letter agreement [and do not revoke your
acceptance], and provided you abide by all of the obligations set forth herein, the Company will provide you with the severance benefits set forth in [Section________)] of the [Insert Date] [Offer Letter] between you and the
Company (the “Severance Benefits”) as follows: [SET OUT THE SEVERANCE BENEFITS AND PAYMENT DATES]. 
  

	1 	 Note: except for factual information, bracketed/bolded provisions and alternatives will be dependent on age
of executive at time of termination and whether termination is an individual termination or part of a group termination. 

 3. Release – In consideration of the Severance Benefits, which you acknowledge
you would not otherwise be entitled to receive, you hereby fully, forever, irrevocably and unconditionally release, remise and discharge the Company, its affiliates, subsidiaries, parent companies, predecessors, and successors, and all of their
respective past and present officers, directors, stockholders, partners, members, employees, agents, representatives, plan administrators, attorneys, insurers and fiduciaries (each in their individual and corporate capacities) (collectively, the
“Released Parties”) from any and all claims, charges, complaints, demands, actions, causes of action, suits, rights, debts, sums of money, costs, accounts, reckonings, covenants, contracts, agreements, promises, doings, omissions, damages,
executions, obligations, liabilities, and expenses (including attorneys’ fees and costs), of every kind and nature that you ever had or now have against any or all of the Released Parties arising up to the date you sign this Agreement,
including, but not limited to, any and all claims arising out of or relating to your employment with and/or separation from the Company, including, but not limited to, all claims under Title VII of the Civil Rights Act of 1964, 42 U.S.C. §
2000e et seq., the Americans With Disabilities Act of 1990, 42 U.S.C. § 12101 et seq., [the Age Discrimination in Employment Act, 29 U.S.C. § 621 et seq.,] the Genetic Information Nondiscrimination Act of 2008, 42
U.S.C. § 2000ff et seq., the Family and Medical Leave Act, 29 U.S.C. § 2601 et seq., the Worker Adjustment and Retraining Notification Act (“WARN”), 29 U.S.C. § 2101 et seq., the Rehabilitation Act of 1973, 29 U.S.C. §
701 et seq., Executive Order 11246, Executive Order 11141, the Fair Credit Reporting Act, 15 U.S.C. § 1681 et seq., and the Employee Retirement Income Security Act of 1974 (“ERISA”), 29 U.S.C. § 1001 et seq., all as amended;
[all claims arising out of the Massachusetts Fair Employment Practices Act., Mass. Gen. Laws ch. 151B, § 1 et seq., the Massachusetts Wage Act, Mass. Gen. Laws ch. 149, § 148 et seq. (Massachusetts law
regarding payment of wages and overtime), the Massachusetts Civil Rights Act, Mass. Gen. Laws ch. 12, §§ 11H and 11I, the Massachusetts Equal Rights Act, Mass. Gen. Laws. ch. 93, § 102 and Mass. Gen.
Laws ch. 214, § 1C, the Massachusetts Labor and Industries Act, Mass. Gen. Laws ch. 149, § 1 et seq., Mass. Gen. Laws ch. 214, § 1B (Massachusetts right of privacy law), the Massachusetts
Maternity Leave Act, Mass. Gen. Laws ch. 149, § 105D, and the Massachusetts Small Necessities Leave Act, Mass. Gen. Laws ch. 149, § 52D, all as amended]; [Insert any other applicable state’s citations;]
all common law claims including, but not limited to, actions in defamation, intentional infliction of emotional distress, misrepresentation, fraud, wrongful discharge, and breach of contract (including, without limitation, all claims arising out of
or relating to your [Insert Date] Employment Agreement); all claims to any non-vested ownership interest in the Company, contractual or otherwise; all state and federal whistleblower claims to the
maximum extent permitted by law; and any claim or damage arising out of your employment with and/or separation from the Company (including a claim for retaliation) under any common law theory or any federal, state or local statute or ordinance not
expressly referenced above; provided, however, that nothing in this letter agreement releases claims to vested benefits or to enforce this Agreement or prevents you from filing a charge with, cooperating with, or participating in any proceeding
before the Equal Employment Opportunity Commission or a state fair employment practices agency (except that you acknowledge that you may not recover any monetary benefits in connection with any such claim, charge or proceeding). 

4. Continuing Obligations – You acknowledge and reaffirm your obligation to keep confidential and not to use or disclose any and
all non-public information concerning the Company that you acquired during the course of your employment with the Company, including, but not limited to, any non-public
information concerning the Company’s business affairs, business prospects, and financial condition. You further acknowledge and reaffirm your obligations set forth in the [Insert Name of Restrictive Covenant Agreement(s)] you executed
for the benefit of the Company, which remain in full force and effect. 
 5. Non-Disparagement
– You understand and agree that, to the extent permitted by law, you will not, in public or private, make any false, disparaging, derogatory or defamatory statements to any person or entity, including, but not limited to, any media outlet,
industry group, financial institution or current or former employee, board member, consultant, client or customer of the Company, regarding the Company or any of the other Released Parties, or regarding the Company’s business affairs, business
prospects, or financial condition. Notwithstanding the above, nothing in this Section will interfere with your ability to comply with legal process or the requirements of applicable federal or state laws or regulations or to cooperate with any
agency investigation. The Company agrees to direct its officers, directors, employees 

 
and consultants not to, in public or private, make any false, disparaging, derogatory or defamatory statements to any person or entity, including, but not limited to, any media outlet, industry
group, financial institution or current or former employee, board member, consultant, client or customer of the Company, regarding you, your involvement with the Company, or your reputation, nor will the Company assist any others in engaging in such
activities. Notwithstanding the above, nothing in this Section shall interfere with the Company’s ability to comply with legal process or the requirements of applicable federal or state laws or regulations. 

6. Continued Assistance – You agree that after the Termination Date you will provide all reasonable cooperation to the Company,
including but not limited to, assisting the Company in transitioning your job duties and performing any other tasks as reasonably requested by the Company. 

7. Cooperation – To the extent permitted by law, you agree to cooperate fully with the Company in the defense or prosecution of any
claims or actions which already have been brought, are currently pending, or which may be brought in the future against or on behalf of the Company, whether before a state or federal court, any state or federal government agency, or a mediator or
arbitrator. Your full cooperation in connection with such claims or actions shall include, but not be limited to, reasonable requests to meet with counsel to prepare its claims or defenses, to prepare for trial or discovery or an administrative
hearing or a mediation or arbitration and to act as a witness when requested by the Company at reasonable times designated by the Company. You agree that you will notify the Company promptly in the event that you are served with a subpoena or in the
event that you are asked to provide a third party with information concerning any actual or potential complaint or claim against the Company. The Company will reimburse you for
out-of-pocket expenses, and will provide legal counsel if necessary to advise you. 

8. Return of Company Property – You confirm that you have returned to the Company all keys, files, records (and copies thereof),
equipment (including, but not limited to, computer hardware, software and printers, wireless handheld devices, cellular phones, pagers, etc.), Company identification, and any other Company-owned property in your possession or control and have left
intact all electronic Company documents, including but not limited to those that you developed or helped to develop during your employment. You further confirm that you have cancelled all accounts for your benefit, if any, in the Company’s
name, including but not limited to, credit cards, telephone charge cards, cellular phone and/or pager accounts, and computer accounts. 
 9.
Business Expenses and Final Compensation – You acknowledge that you have been reimbursed by the Company for all business expenses incurred in conjunction with the performance of your employment and that no other reimbursements are owed
to you. You further acknowledge that you have received payment in full for all services rendered in conjunction with your employment by the Company, including payment for all wages (including overtime), bonuses, commissions, and accrued, unused
vacation time, and that no other compensation is owed to you except as provided herein. 
 10. Amendment and Waiver – This letter
agreement shall be binding upon the parties and may not be modified in any manner, except by an instrument in writing of concurrent or subsequent date signed by duly authorized representatives of the parties hereto. This letter agreement is binding
upon and shall inure to the benefit of the parties and their respective agents, assigns, heirs, executors, successors and administrators. No delay or omission by the Company in exercising any right under this letter agreement shall operate as a
waiver of that or any other right. A waiver or consent given by the Company on any one occasion shall be effective only in that instance and shall not be construed as a bar to or waiver of any right on any other occasion. 

11. Validity – Should any provision of this letter agreement be declared or be determined by any court of competent jurisdiction to
be illegal or invalid, the validity of the remaining parts, terms or provisions shall not be affected thereby and said illegal or invalid part, term or provision shall be deemed not to be a part of this letter agreement. 

 12. Confidentiality – To the extent permitted by law, you understand and agree
that as a condition of the Severance Benefits herein described, the terms and contents of this letter agreement, and the contents of the negotiations and discussions resulting in this letter agreement, shall be maintained as confidential by you and
your agents and representatives and shall not be disclosed except to your immediate family, your attorneys, financial advisors, and as required by law, and except as otherwise agreed to in writing by the Company. 

13. Nature of Agreement — You understand and agree that this letter agreement is a severance agreement and does not constitute an
admission of liability or wrongdoing on the part of the Company. 
 14. Acknowledgments — You acknowledge that you have been
given at least [seven (7) / twenty-one (21) / forty-five (45)] days to consider this letter agreement, and that the Company advised you to consult with an attorney of your own choosing prior to signing
this letter agreement. [You understand that you may revoke this letter agreement for a period of seven (7) days after you sign this letter agreement by notifying me in writing, and the letter agreement shall not be effective or enforceable
until the expiration of this seven (7) day revocation period. You understand and agree that by entering into this letter agreement, you are waiving any and all rights or claims you might have under the Age Discrimination in Employment Act, as
amended by the Older Workers Benefit Protection Act, and that you have received consideration beyond that to which you were previously entitled.] 

15. [Eligibility for Severance Program — Attached to this letter agreement as Attachment A is a description of
(i) any class, unit or group of individuals covered by the program of severance benefits which the Company has offered to you, and any applicable time limits regarding such severance benefit program; and
(ii) the job title and ages of all individuals eligible or selected for such severance benefit program, and the ages of all individuals in the same job classification or organizational unit who are not eligible or who were not
selected for such severance benefit program.] 
 16. Voluntary Assent — You affirm that no other promises or agreements of
any kind have been made to or with you by any person or entity whatsoever to cause you to sign this letter agreement, and that you fully understand the meaning and intent of this letter agreement. You state and represent that you have had an
opportunity to fully discuss and review the terms of this letter agreement with an attorney. You further state and represent that you have carefully read this letter agreement, understand the contents herein, freely and voluntarily assent to all of
the terms and conditions hereof, and sign your name of your own free act. 
 17. Applicable Law — This letter agreement shall be
interpreted and construed by the laws of the [Commonwealth of Massachusetts], without regard to conflict of laws provisions. You hereby irrevocably submit to and acknowledge and recognize the jurisdiction of the courts of the [Commonwealth
of Massachusetts], or if appropriate, a federal court located in the [Commonwealth of Massachusetts] (which courts, for purposes of this letter agreement, are the only courts of competent jurisdiction), over any suit, action or other
proceeding arising out of, under or in connection with this letter agreement or the subject matter hereof. 
 18. Entire Agreement —
This letter agreement contains and constitutes the entire understanding and agreement between the parties hereto with respect to your severance benefits and the settlement of claims against the Company and cancels all previous oral and written
negotiations, agreements, and commitments in connection therewith. Nothing in this paragraph, however, shall modify, cancel or supersede your obligations set forth in paragraph 4 above. 

19. Tax Acknowledgement — In connection with the Severance Benefits provided to you pursuant to this letter agreement, the Company
shall withhold and remit to the tax authorities the amounts required under applicable law, and you shall be responsible for all applicable taxes with respect to such Severance Benefits under applicable law. You acknowledge that you are not relying
upon the advice or representation of the Company with respect to the tax treatment of any of the Severance Benefits set forth in paragraph 2 of this letter agreement. 

 If you have any questions about the matters covered in this letter agreement, please call me
at [Insert Phone Number]. 
  

			
	Very truly yours,
		
	By:	 	  

		 	[NAME] [TITLE]

 I hereby agree to the terms and conditions set forth above. [I have been given at least [twenty- one
(21) / forty-five (45)] days to consider this letter agreement and I have chosen to execute this on the date below. I intend that this letter agreement will become a binding agreement between me and the Company if I do not revoke my acceptance in
seven (7) days.] 
  

					
	  
	 	        	  	  

	[Insert Name]	 		  	Date

 To be returned in a timely manner as set forth on the first page of this letter agreement. 

 EXHIBIT B 

INVENTION AND NON-DISCLOSURE
AGREEMENT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00313-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00313-of-00352.parquet"}]]